Open AccessTherapeutic Targets In Breast Cancer Signaling: A Review
Author(s) -
Emmanuel Ifeanyi Obeagu,
Quratulain Babar,
C. C. N. Vincent,
Chikwendu Lawrence Udenze,
Richard Eze,
Chukwuma J. Okafor,
Bart I. Ifionu,
Augustine Amaeze Amaeze,
Florence Ngozi Amaeze
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i56a33889
Subject(s) - breast cancer , cancer , cancer research , medicine , hormone , hormone receptor , receptor , oncology , biology , bioinformatics
For women, the most dominant type of cancer is breast cancer and perhaps one of the most recognizedreasons of death. This is a disorder of many distinct traits, many of which are known as positive hormone receptor, human epidermal receptor-2 (HER2+), and three negative breast cancers (TNBC). Drugs that directly target and kill tumors constitute a rapidly-growing form of molecular therapy for cancer patients. Analysis reveals that stable breast tissue cells exhibit receptors which aren't usually present. As a result, it is imperative to cognize the molecular roots of breast cancer and the myriad compromised pathology-related processes and pathways to ensure progresses in early diagnosis and prevention. This study demonstrates essential cellular pathways relevant for breast cancer including improvements in cell proliferation, apoptosis, and hormone balances in breast tissues. On the basis of these notions, we consider how breast cancer is associated to the creation of potentially therapeutic interventions and predictive biomarkers.